Zydus bets big on proprietary drugs to boost revenue
Sharvil Patel, managing director of Zydus Lifesciences said, half of the research and development (R&D) allocation is geared towards developing new chemical entities (NCEs), biologics and differentiated products. On average, Zydus spends about 8% of its revenue on R&D, which is higher than the industry average of 6%.